RCKT
Rocket Pharmaceuticals, Inc. Healthcare - Gene Therapy Investor Relations →
Rocket Pharmaceuticals, Inc. (RCKT) closed at $4.14 as of 2026-03-20, trading 72.5% below its 200-week moving average of $15.07. This places RCKT in the extreme value zone. The stock is currently moving closer to the line, down from -68.7% last week. The 14-week RSI sits at 58, indicating neutral momentum.
A big spike in selling this week — 2.5x the usual volume, and the price dropped. Sometimes this kind of heavy selling marks the end of a decline. The idea is that the last reluctant holders have finally sold, leaving fewer sellers left to push the price lower.
Over the past 530 weeks of data, RCKT has crossed below its 200-week moving average 8 times. On average, these episodes lasted 50 weeks. The average one-year return after crossing below was -11.4%, suggesting these dips have not historically been reliable buying opportunities for this stock.
With a market cap of $449 million, RCKT is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -60.3%. The stock trades at 1.6x book value.
Share count has increased 36.9% over three years, indicating dilution.
Over the past 10.2 years, a hypothetical investment of $100 in RCKT would have grown to $13, compared to $396 for the S&P 500. RCKT has returned -17.9% annualized vs 14.4% for the index, underperforming the broader market over this period.
Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: RCKT vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After RCKT Crosses Below the Line?
Across 8 historical episodes, buying RCKT when it crossed below its 200-week moving average produced an average return of -21.2% after 12 months (median -62.0%), compared to +18.9% for the S&P 500 over the same periods. 12% of those episodes were profitable after one year. After 24 months, the average return was -6.6% vs +38.1% for the index.
Each line shows $100 invested at the moment RCKT crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
RCKT has crossed below its 200-week MA 8 times with an average 1-year return of +-11.4% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Jan 2016 | Apr 2016 | 10 | 23.7% | -79.9% | -86.8% |
| Jun 2016 | Jul 2016 | 6 | 16.8% | -77.8% | -87.3% |
| Aug 2016 | Sep 2016 | 7 | 20.8% | -85.7% | -84.8% |
| Oct 2016 | Aug 2018 | 98 | 86.4% | -64.6% | -86.6% |
| Oct 2018 | Dec 2019 | 61 | 50.7% | -42.6% | -79.6% |
| Mar 2020 | May 2020 | 8 | 22.6% | +292.5% | -69.7% |
| Nov 2021 | Dec 2023 | 107 | 63.5% | -21.4% | -82.5% |
| Apr 2024 | Ongoing | 103+ | 86.8% | Ongoing | -83.4% |
| Average | 50 | — | +-11.4% | — |
Frequently Asked Questions
Is RCKT below its 200-week moving average?
Yes. As of 2026-03-20, Rocket Pharmaceuticals, Inc. (RCKT) is trading 72.5% below its 200-week moving average of $15.07. The current price is $4.14.
What is RCKT's 200-week moving average price?
Rocket Pharmaceuticals, Inc.'s 200-week moving average is $15.07 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when RCKT drops below its 200-week moving average?
RCKT has crossed below its 200-week moving average 8 times in our data. The average one-year return after these crossings was -11.4%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 50 weeks on average.
Is RCKT a good value right now?
Here's what our data says about RCKT as of 2026-03-20: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 58. Free cash flow is currently negative. Return on equity is -60.3%. Price-to-book is 1.6x. This is not a buy or sell recommendation — always do your own research.
How does RCKT compare to the S&P 500?
Over the past 10.2 years, $100 invested in RCKT would have grown to $13, compared to $396 for the S&P 500. That's -17.9% annualized vs 14.4% for the index. RCKT has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20